

VOTING QUESTION #1 TO THE COMMITTEE

FOR REBIOTIX

September 22, 2022

Are the available data adequate to support the effectiveness of REBYOTA to reduce the recurrence of *Clostridioides difficile* infection (CDI) in adults 18 years of age and older following antibiotic treatment for recurrent CDI?

Please vote Yes or No